Company intelligence / Profile preview

Terapet

Ownership: Private
Development stage: Commercial

Overview

Terapet has developed a next-generation gamma-ray detection platform enabling real-time, non-invasive, in-vivo dose monitoring during proton therapy. Their first product, Qualyscan, has entered commercialization with pilot customers in Sweden and South Korea. The second device, Nuclyscan, is at the IND stage with plans to shift trials to South Korea. The company’s technology aims to improve precision and safety of cancer radiotherapy by providing clinicians with unprecedented visualization of proton delivery inside patients.

Therapeutic areas: Oncology
Modalities: DeviceImaging technologyGamma ray detection system
Industry: Medical Imaging

Partnerships

Inselspital Department of Nuclear Medicine (Switzerland)Politecnico di Milano & Nuclear Instruments Srl (Italy) – R&D partners via Eurostars Program grant

Beyond the preview

Go deeper on Terapet.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Terapet.

Explore the full profile